Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients

Jitsu Katoa, Norimitsu Matusb, Yoshihiro Kakehib,*, Emiko Murayamac, Shoichi Ohwadad, Masahiro Sugiharad

Abstract

This study investigated the safety and efficacy of mirogabalin, a novel, potent, selective ligand of the \( \alpha_{2}\delta \) subunit of voltage-dependent \( \text{Ca}^{2+} \) channels, for the treatment of postherpetic neuralgia (PHN). In this multicenter, double-blind, placebo-controlled phase 3 study, Asian patients \( \geq 20 \) years with PHN were randomized 2:1:1:1 to placebo or mirogabalin 15, 20, or 30 mg/day for up to 14 weeks (NCT02318719). The primary efficacy endpoint was the change from baseline in average daily pain score at week 14, defined as a weekly average of daily pain (0 = “no pain” to 10 = “worst possible pain,” for the last 24 hours). Of 765 patients randomized, 763 received \( \geq 1 \) dose of the study drug and were included in the analysis: 303, 152, 153, and 155 received placebo, mirogabalin 15, 20, or 30 mg/day, respectively. A total of 671 (87.7%) patients completed the study. At week 14, the difference in average daily pain score least squares mean vs placebo was –0.41, –0.47, and –0.77, respectively; all mirogabalin groups showed statistical significance. The most common treatment-emergent adverse events were somnolence, nasopharyngitis, dizziness, weight increase, and edema, and all of them were mild or moderate in severity. Mirogabalin was superior to placebo in all groups for relieving PHN and appeared well tolerated.

Keywords: Pain, Postherpetic neuralgia, Pain medicine, \( \alpha_{2}\delta \)-ligand

1. Introduction

Neuropathic pain has many causes, including neuropathy due to diabetes mellitus or to herpes zoster and spinal cord injury. Symptoms of postherpetic neuralgia (PHN) include spontaneous pain, hyperalgesia, and allodynia.

Multiple factors play a role in neuropathic pain, including the involvement of voltage-dependent sodium and calcium channels.\(^1\) Animal studies support the role of voltage-dependent \( \text{Ca}^{2+} \) channels (VDCCs) in neuropathic pain signaling. In animal studies, the \( \alpha_{2}\delta \) subunit of VDCCs enhances the activity of VDCCs by enabling increased trafficking to the membrane, leading to increased peripheral and central neuron excitability that is believed to contribute to neuropathic pain.\(^2,16,17\) Although the mechanism of action is not fully understood, it is believed that \( \alpha_{2}\delta \) ligands alleviate neuropathic pain by reducing the enhanced \( \text{Ca}^{2+} \) influx and neuronal excitability mediated by the \( \alpha_{2}\delta \) subunit.\(^2,16,17\)

Current options for managing neuropathic pain include anticonvulsants, tricyclic antidepressants, and serotonin/norepinephrine reuptake inhibitors. No single class of medication has shown efficacy for all neuropathic pain patients, and studies estimate the effect size reported in meta-analyses of pharmacotherapy for neuropathic pain may have been overestimated.\(^12\) Many patients take multiple medications for neuropathic pain, which increases the risk of adverse events (AEs).\(^3\) Current guidelines issued by the Japanese Society of Pain Clinicians for the management of neuropathic pain recommend the use of pharmacologic therapies as the best treatment strategy for neuropathic pain that focuses on the improvement of pain and quality of life (QoL).\(^14\) Therefore, there is an unmet medical need for a management option with less AEs and high efficacy.

Mirogabalin monobenzenesulfonate (herein referred to as mirogabalin, Daiichi Sankyo Co, Ltd, Tokyo, Japan) is a novel, selective oral \( \alpha_{2}\delta \) ligand being developed for the treatment of PHN and diabetic peripheral neuropathic pain (DPNP). In contrast to pregabalin, a standard \( \alpha_{2}\delta \) ligand, mirogabalin showed higher binding affinities in human and rat \( \alpha_{2}\delta \) subunits; furthermore, it had a slower dissociation rate for the \( \alpha_{2}\delta-1 \) subunit than the \( \alpha_{2}\delta-2 \) subunit. When studied in experimental neuropathic pain models, partial sciatic nerve ligation rats, and streptozotocin-induced diabetic rats, mirogabalin showed more potent and longer-lasting analgesic effects.\(^5\) A phase 2 trial of mirogabalin has proven the drug’s effectiveness in reducing sleep disturbances and improving pain scores associated with DPNP.\(^19,25,26\)

This phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of mirogabalin in Asian patients with PHN.
2. Research design and methods

2.1. Study design

This was a multicenter, double-blind, placebo-controlled, 14-week, parallel group study for the treatment of PHN (NCT02318719) in Asian patients, conducted between January 23, 2015, and January 9, 2017. This study followed the Declaration of Helsinki and the International Council for Harmonisation Consolidated Guideline E6 for Good Clinical Practice. There were approximately 200 study sites in Japan, Korea, Taiwan, Singapore, Malaysia, and Thailand, and the study was approved by the institutional review board, or equivalent, for each site before beginning. Before enrollment, informed consent was obtained from all patients. Safety was periodically monitored by an independent Data Safety Monitoring Board.

To be eligible for the study, patients had to meet all the following criteria: Asian ≥20 years of age with PHN (defined as persistent pain after 3 months from the disappearance of the herpes zoster rash); able to give written informed consent for study participation, understand procedures of this study, and complete patient-reported questionnaires adequately; a pain scale of ≥40 mm on visual analogue scale (VAS) of Short-form McGill Pain Questionnaire (SF-MPQ) at screening and randomization; and an average daily pain score (ADPS) of ≥4 on the 11-point numeric rating scale (NRS) over the past 7 days.

Patients were excluded if they met any of the following criteria: pain scale ≥90 mm on VAS of SF-MPQ at screening and randomization, or their daily pain score was ≥9 during observation period; previous use of a neurolytic block or neurosurgical therapy for current PHN; severe pain or neurologic disorder at screening or randomization not related to PHN; major neurosurgical therapy for current PHN; severe pain or neurologic disorder; hepatobiliary, respiratory, or hematologic illness or unstable medical condition; known immunocompromised status or history of pernicious anemia, untreated hypothyroidism, or HIV infection; known immunocompromised status or history of positive hepatitis B antigen or hepatitis C antibody; in women, pregnancy, potential pregnancy, or breastfeeding; or male or female unwilling to take reliable contraceptive measures during and for 4 weeks after the study; participation in another clinical study within 30 days before informed consent, or participation in any clinical study where mirogabalin was received; abuse of illicit drugs or alcohol within 1 year of screening; yes response to any question on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening or randomization in relation to events occurring within past year; previous treatment with a drug that could cause irreversible retinal degeneration; clinical laboratory values exceeding specified study limits at screening; or a “yes” response to the suicidality question on the Major Depressive Episode Module or to any question of B1b, B3-B11c, B13, or B14 in the Suicidality Module on the Mini-International Neuropsychiatric Interview at screening.

After informed consent, but before the screening visit, patients who received any of the following prohibited concomitant medications underwent a 7-day washout period: pregabalin; antiepileptics; hypnotics and anxiolytics; opioids; tramadol and any of its combination drugs; Neurotropin; N-methyl-D-aspartate receptor antagonists; muscle relaxants; topical capsaicin, steroids, prostaglandins, or local anesthetics, except as topical products for a nondisease site of PHN; sodium channel blockers; centrally acting sympatholytics; vitamin B1 or B12; α-lipoic acid; evening primrose oil; nefopam; immunosuppressants; drugs that could cause irreversible retinal degeneration; and study drugs in other studies. The patients could not resume these medications during the study. Patients could continue taking antidepressants, ultrashortacting hypnotics, nonsteroidal anti-inflammatory drugs, and Chinese herbal medications during the study provided the dosage had not changed for 14 days before screening, and the dosage was not changed and the drug was not stopped unless safety problems were observed.

After informed consent but before the screening visit, patients who received any of the following prohibited concomitant therapies underwent a 7-day washout period: nerve blocks; iontophoresis; laser therapy; acupuncture; spinal cord stimulation; surgery that could confound PHN assessment; transcutaneous electrical nerve stimulation; and other forms of pain reduction therapy for PHN except psychological, mental, and physical therapy. These therapies could not be resumed during the study. Patients could continue psychological, mental, or physical therapies provided the frequency of therapy had not changed from 14 days before the screening visit, and the therapy was not started after the screening visit.

After a 7-day observation period, patients were randomized 2:1: 1:1 to 1 of 4 treatment groups: placebo, or mirogabalin 15 mg once daily, 10 mg twice daily, or 15 mg twice daily in accordance with the randomization schedule securely maintained in Interactive Web Response System (Bell Medical Solutions, Inc, Tokyo, Japan). Randomization was stratified by dichotomized baseline ADPS (<6 vs ≥6). The randomization schedule was generated and securely kept by the independent biostatistician of Bell Medical Solutions, Inc, throughout the study to maintain the blinding.

The study consisted of a 1-week observation period, followed by a 1- to 2-week dose titration period, a 12- to 13-week fixed-dose period, and a 1-week follow-up period, where patients were monitored after treatment (Fig. 1). For the mirogabalin 15 mg/day group, 5 mg/day was administered for the first week (once daily at bedtime), followed by 10 mg/day (10 mg once daily) during the second week of the titration period. For the mirogabalin 20- and 30-mg/day groups, 10 mg/day was administered (5 mg twice daily; once in the morning and at bedtime) during the first week of the titration period. On the second week, mirogabalin was administered 20 mg/day (10 mg twice daily; once in the morning and at bedtime) to the 30 mg/day group (15 mg twice daily; once in the morning and once at bedtime). Patients who were randomized to the 15 mg/day group received a matching placebo tablet in the morning. During the study, acetaminophen was permitted as rescue medication, up to the maximum dose in the package insert, as needed; patients were instructed to record in the electronic patient diary the dose of acetaminophen used.

2.2. Efficacy assessments

The primary efficacy endpoint was the change from baseline in ADPS at week 14, a weekly average of daily patient ratings recorded in an electronic diary. The patient was instructed to rate the pain over the past 24 hours on an NRS (0 = “no pain” to 10 = “worst possible pain”) every morning upon awakening, before taking the study drug.
Secondary efficacy endpoints included responder rate, defined as the percentage of patients with ≥30% and ≥50% reduction from baseline in ADPS; patient-rated pain on the VAS of SF-MPQ; and average daily sleep interference score (ADSS). The ADSS was the weekly average of sleep interference as recorded by patients in electronic diaries rated every morning on an NRS of 0–10, “pain did not interfere with sleep” to 10 = “pain completely interfered with sleep” over the last 24 hours. Another secondary endpoint was the Patient Global Impression of Change (PGIC), in which patients rated their improvement on a scale from 0 = “very much worse” to 7 = “very much improved” at the end of treatment.

Other secondary endpoints included SF-MPQ (other than VAS), brief pain inventory-short form, medical outcomes study sleep scale, hospital anxiety and depression scale (HADS), 36-item short form health survey (SF-36), and assessment of allodynia and hyperalgesia by the investigator on a 2-point scale (1 = “present,” 2 = “absent”). Allodynia was evaluated by stroking the skin with a brush, and hyperalgesia was evaluated by pressing the skin with a bamboo cooking stick.

2.3. Safety assessments
Adverse events (AEs) were monitored throughout the study and classified according to the Medical Dictionary for Regulatory Activities, version 17.1. Patients had a total of 11 visits over the 14 weeks, including screening and randomization (week 0). At each visit, clinical laboratory evaluations, physical examinations, and vital signs were monitored. Suicidal behavior and ideation were monitored at each visit using the C-SSRS. In addition, a neurological examination and an electrocardiogram were performed at screening and at the end of treatment or at early termination, and included assessment of muscle strength (0–5 rating; ankle dorsiflexion) and gait/station.

2.4. Statistical analysis
Sample size was determined to achieve 90% statistical power under the assumption of 0.8 difference vs placebo in change from baseline in ADPS for all mirogabalin groups and a common standard deviation of 1.8 units. The power calculation was based on analysis of variance, and a gatekeeping procedure was used to control the type I error rate at less than 0.05.

The modified intent-to-treat analysis set, defined as patients who were randomized and received ≥1 dose of the study drug, was used for efficacy analysis. For the primary endpoint (change from baseline in ADPS at week 14 between each group), the multiple imputation method was used to handle missing weekly ADPS data. In the multiple imputation data generation, the Markov Chain Monte Carlo method with treatment group, age, and sex covariates was used to produce a monotone missing data pattern first. The regression with predictive mean matching with the same set of covariates was applied to the monotone missing data. A pattern mixture model with different shift parameters depending on reasons for study discontinuation (AE, lack of efficacy, or other) and was applied to the imputed weekly ADPS data by regression with predictive mean matching to impose penalty on the study discontinuation under a missing not-at-random mechanism. To compare change from baseline in ADPS at week 14 between each group receiving ≥1 dose of mirogabalin and the placebo group, a mixed-effect model with repeated measures (MMRM) was used for the imputed data sets. The MMRM included treatment, week, and treatment-by-week as fixed effects; week as a repeated measure; and baseline ADPS as a covariate. The results from the MMRM analyses were combined using Rubin’s rule. The following gatekeeping procedure was prespecified to adjust for multiplicity of comparisons between each of mirogabalin groups and placebo; mirogabalin 20 and 30 mg/day, which have been evaluated and demonstrated efficacy trend in the phase 2 study, were tested against placebo at a significance level of 0.025. If both were statistically significant, mirogabalin 15 mg/day would be tested at a level of 0.05. If neither of them was statistically significant, mirogabalin 15 mg/day would not be tested. If either mirogabalin 20 or 30 mg/day was statistically significant, mirogabalin 15 mg/day would be tested at a level of 0.025.

For secondary endpoints, responder rates (≥30% and ≥50% improvement in ADPS) for mirogabalin groups were compared with the placebo group using a logistic regression model with the treatment group as a factor and baseline ADPS as a covariate. In the analysis, patients who discontinued the study were considered nonresponders and a last observation carried forward (LOCF) approach was used for the imputation for patients who completed the study but did not have week 14 ADPS. The ADSS was analyzed using MMRM with treatment, week, and treatment-by-week as fixed effects; week as a repeated measure; and baseline ADSIS as a covariate. For the other secondary endpoints, analysis of covariance model with the baseline value as a covariate was used for continuous variables, and a logistic
Figure 2. Patient disposition. AE, adverse event.

Table 1
Demographics and baseline disease characteristics.

| Parameter                  | Placebo, N = 304 | Mirogabalin, 15 mg/day*, N = 153 | Mirogabalin, 20 mg/day†, N = 153 | Mirogabalin, 30 mg/day‡, N = 155 | Total, N = 765 |
|----------------------------|------------------|----------------------------------|----------------------------------|----------------------------------|----------------|
| Mean age§, y               | 66.2             | 66.6                             | 68.9                             | 64.5                             | 66.5           |
| Age at informed consent    |                  |                                  |                                  |                                  |                |
| ≥18—<65 y                  | 102 (33.6)       | 47 (30.7)                        | 39 (25.5)                        | 64 (41.3)                        | 252 (32.9)     |
| ≥65—<75 y                  | 153 (50.3)       | 82 (53.6)                        | 72 (47.1)                        | 66 (42.6)                        | 373 (48.8)     |
| ≥75 y                      | 49 (16.1)        | 24 (15.7)                        | 42 (27.5)                        | 25 (16.1)                        | 140 (18.3)     |
| Sex                        |                  |                                  |                                  |                                  |                |
| Male                       | 177 (58.2)       | 97 (63.4)                        | 91 (59.5)                        | 96 (61.9)                        | 461 (60.3)     |
| Female                     | 127 (41.8)       | 56 (36.6)                        | 62 (40.5)                        | 59 (38.1)                        | 304 (39.7)     |
| Country                    |                  |                                  |                                  |                                  |                |
| Japan                      | 245 (80.6)       | 122 (79.7)                       | 121 (79.1)                       | 124 (80.0)                       | 612 (80.0)     |
| Korea                      | 41 (13.5)        | 24 (15.7)                        | 22 (14.4)                        | 21 (13.5)                        | 108 (14.1)     |
| Taiwan                     | 11 (3.6)         | 4 (2.6)                          | 5 (3.3)                          | 5 (3.2)                          | 25 (3.3)       |
| Malaysia                   | 2 (0.7)          | 1 (0.7)                          | 3 (2.0)                          | 4 (2.6)                          | 10 (1.3)       |
| Thailand                   | 3 (1.0)          | 2 (1.3)                          | 2 (1.3)                          | 0                                | 7 (0.9)        |
| Singapore                  | 2 (0.7)          | 0                                | 1 (0.6)                          | 0                                | 3 (0.4)        |
| Weight, kg, mean (SD)      | 62.1 (10.6)      | 62.8 (10.5)                      | 62.0 (9.9)                       | 62.2 (10.5)                      | 62.3 (10.4)    |
| CrCl, mL/minute, mean (SD) | 85.4 (22.3)      | 83.0 (18.7)                      | 80.3 (18.1)                      | 85.8 (21.0)                      | 84.0 (20.7)    |
| ADPS, mean (SD)            | 5.75 (1.13)      | 5.69 (1.04)                      | 5.70 (1.02)                      | 5.65 (1.03)                      | 5.71 (1.07)    |
| VAS of SF-MPQ§, mean (SD)  | 59.4 (10.6)      | 58.4 (10.8)                      | 59.3 (9.8)                       | 59.0 (10.7)                      | 59.1 (10.5)    |
| Duration of PHN, mo, median| 15.0             | 18.0                             | 22.0                             | 21.0                             | 18.0           |
| Site of PHN                |                  |                                  |                                  |                                  |                |
| Trigeminal segment area    | 72 (23.7)        | 25 (16.3)                        | 46 (30.1)                        | 52 (33.5)                        | 193 (25.2)     |
| Cervical segment area      | 49 (16.1)        | 26 (17.0)                        | 16 (10.5)                        | 26 (16.8)                        | 118 (15.4)     |
| Thoracic segment area      | 141 (46.4)       | 75 (49.0)                        | 69 (45.1)                        | 66 (42.6)                        | 351 (45.9)     |
| Lumbar segment area        | 43 (14.1)        | 22 (14.4)                        | 22 (14.4)                        | 16 (10.3)                        | 103 (13.5)     |
| Sacral segment area        | 11 (3.6)         | 9 (5.9)                          | 3 (2.0)                          | 4 (2.6)                          | 28 (3.7)       |

Values are n (%) unless otherwise noted. Results are from the randomized set.
* 15 mg once daily.
† 10 mg twice daily.
‡ 15 mg twice daily.
§ Age at informed consent.
║ Calculated using the Cockcroft–Gault equation.
{ At randomization.
ADPS, average daily pain score; CrCl, creatinine clearance; PHN, postherpetic neuralgia; SD, standard deviation; SF-MPQ, short-form McGill Pain Questionnaire; VAS, visual analogue scale.
regression model with treatment group as a covariate was applied for categorical variables. Statistical analysis was performed using Statistical Analysis Software (Version 9.3).

All safety data were summarized on the safety analysis set including patients who received 1 dose of study drug. Treatment-emergent AEs (TEAEs) were summarized as a frequency table.

3. Results

3.1. Patients

A total of 765 patients were randomized to placebo (N = 304) and mirogabalin 15 mg/day (N = 153), 20 mg/day (N = 153), and 30 mg/day (N = 155) (Fig. 2). A total of 763 patients were included in the modified intent-to-treat analysis set population, and 671 (87.7%) patients completed the study. A total of 94 patients (12.3%) discontinued the study; 38 (12.5%) in the placebo group, 16 (10.5%) in the 15 mg/day group, 25 (16.3%) in the 20 mg/day group, and 15 (9.7%) in the 30 mg/day group. The most common reasons for discontinuation were patient withdrawal (25 patients in the placebo group, 7 patients in the 15 mg/day group, 9 patients in the 20 mg/day group, and 10 patients in the 30 mg/day group) and AEs (7 patients in the placebo group, 6 patients in the 15 mg/day group, 12 patients in the 20 mg/day group, and 4 patients in the 30 mg/day group). Randomized patients were mostly male (60.3%) and Japanese (89.0%), with a mean age of 66.5 years (Table 1). Across all treatment groups, the most common site of PHN (45.9%) was the thoracic segment area. The mean ADPS and VAS of the SF-MPQ at baseline were 5.71 and 66.5, respectively.

3.2. Efficacy

The ADPS gradually decreased through week 14 in all treatment groups, and all mirogabalin groups had a greater and more rapid decrease of ADPS compared with placebo starting at week 1 (Fig. 3). As the daily dose of mirogabalin increased, there was a greater decrease in least squares (LS) mean ADPS compared with placebo. At week 14, the LS mean change from baseline in ADPS was −1.20, −1.61, −1.68, and −1.97 for the placebo and mirogabalin 15, 20, and 30 mg/day groups, respectively. A statistically significant difference in mean change in ADPS from baseline for all mirogabalin groups vs placebo occurred at week 14; the LS mean vs placebo was −0.41 (95% confidence interval [CI] −0.74 to −0.07, P = 0.0170), −0.47 (95% CI −0.81 to −0.14, P = 0.0058), and −0.77 (95% CI −1.10 to −0.44, P < 0.0001) for mirogabalin 15, 20, and 30 mg/day groups, respectively.

The proportion of patients with a ≥30% reduction from baseline in ADPS was 35.0%, 45.4%, 45.1%, and 49.7% for the placebo and mirogabalin 15, 20, and 30 mg/day groups, respectively, with all groups being significantly higher than placebo (Table 2 and Fig. 4). The proportion of patients with a ≥50% reduction from baseline in ADPS was 19.8%, 23.0%, 26.8%, and 29.0% for the placebo and mirogabalin 15, 20, and 30 mg/day groups, respectively, with the 30 mg/day group being significantly higher than placebo (odds ratio 1.63 [95% CI 1.04–2.56], P = 0.0336). The LS mean change from baseline to week 14 in VAS of the SF-MPQ and the ADSIS was significantly greater in all mirogabalin groups compared with placebo (Table 2).

Significantly more patients treated with mirogabalin 15 mg/day vs placebo reported a PGIC of “much improved or better (score =2)” at week 14 (36.2% vs 26.4%, P = 0.0318), and significantly more patients treated with mirogabalin 20 and 30 mg/day vs placebo reported a PGIC score of “minimally improved or better (score =3)” (69.3% and 69.0% vs 54.5%, respectively; P = 0.0025 and 0.0028, respectively) (Fig. 5).

At week 14, the changes from baseline in the SF-MPQ (excluding VAS) showed greater improvement in all mirogabalin groups vs placebo. For the SF-MPQ subscales (sensory score, affective score, total score, and present pain intensity), the LS mean differences in change from baseline at week 14 were significantly greater in all mirogabalin groups vs placebo.

The changes from baseline in the brief pain inventory-short form subscales at week 14 showed greater improvement in all mirogabalin groups vs placebo. The LS mean differences in change from baseline for worst pain, average pain, and pain right now were statistically significant for all mirogabalin groups vs placebo, with the greatest difference seen in the mirogabalin 30 mg/day group. The LS mean difference in change from baseline for impact on daily function vs placebo was statistically significant in the mirogabalin 20 mg/day and 30 mg/day group vs placebo.
Averaged daily pain score, visual analog pain scores, averaged daily sleep interference scores, and responder rate.

|                | Baseline | LS mean change from baseline | Difference vs placebo (95% CI) | P    |
|----------------|----------|------------------------------|--------------------------------|------|
| **ADPS**       |          |                              |                                |      |
| Placebo*       | 5.75     | −1.20                        | —                              |      |
| Mirogabalin 15 mg/day† | 5.69     | −1.61                        | −0.41 (−0.74, −0.07)           | 0.0170|
| Mirogabalin 20 mg/day‡ | 5.70     | −1.68                        | −0.47 (−0.81, −0.14)           | 0.0058|
| Mirogabalin 30 mg/day§ | 5.65     | −1.97                        | −0.77 (−1.10, −0.44)           | <0.0001|

| **ADPS responder rate (≥30%)** |          |                              |                                |      |
| Placebo*       | —        | 106 (53.0)                   | —                              |      |
| Mirogabalin 15 mg/day† | —        | 69 (48.4)                    | 1.54 (1.03−2.29)               | 0.0363|
| Mirogabalin 20 mg/day‡ | —        | 69 (49.1)                    | 1.52 (1.02−2.27)               | 0.0405|
| Mirogabalin 30 mg/day§ | —        | 77 (49.7)                    | 1.81 (1.21−2.69)               | 0.0035|

| **ADPS responder rate (≥50%)** |          |                              |                                |      |
| Placebo*       | —        | 60 (19.8)                    | —                              |      |
| Mirogabalin 15 mg/day† | —        | 35 (23.0)                    | 1.20 (0.75−1.93)               | 0.4526|
| Mirogabalin 20 mg/day‡ | —        | 41 (28.8)                    | 1.48 (0.93−2.34)               | 0.0964|
| Mirogabalin 30 mg/day§ | —        | 45 (29.0)                    | 1.63 (1.04−2.56)               | 0.0336|

| **PGIC (score ≤2)** |          |                              |                                |      |
| Placebo*       | —        | 80 (26.4)                    | —                              |      |
| Mirogabalin 15 mg/day† | —        | 55 (36.2)                    | 1.58 (1.04−2.40)               | 0.0318|
| Mirogabalin 20 mg/day‡ | —        | 51 (33.3)                    | 1.39 (0.91−2.13)               | 0.1233|
| Mirogabalin 30 mg/day§ | —        | 53 (34.2)                    | 1.45 (0.95−2.20)               | 0.0830|

| **PGIC (score ≤3)** |          |                              |                                |      |
| Placebo*       | —        | 165 (54.5)                   | —                              |      |
| Mirogabalin 15 mg/day† | —        | 95 (62.5)                    | 1.39 (0.94−2.08)               | 0.1025|
| Mirogabalin 20 mg/day‡ | —        | 106 (69.3)                   | 1.89 (1.25−2.85)               | 0.0025|
| Mirogabalin 30 mg/day§ | —        | 107 (69.0)                   | 1.86 (1.24−2.61)               | 0.0028|

* n = 303.
† 15 mg once daily (n = 153).
‡ 10 mg twice daily (n = 153).
§ 15 mg twice daily (n = 155).
ADPS, average daily pain score; ADSIS, average daily sleep interference score; CI, confidence interval; LS, least squares; PGIC, patient global impression of change; SD, standard deviation; SF-MPQ, Short-form McGill Pain Questionnaire; VAS, visual analogue scale.

At week 14, the LS mean differences in change from baseline vs placebo for the medical outcomes study subscales of sleep disturbance and sleep somnolence increased improvement as the daily dose of mirogabalin increased.

The changes from baseline for the HADS subscales of depression and anxiety at week 14 were greater in all mirogabalin groups vs placebo. The LS mean differences in change from baseline were statistically significant vs placebo in all mirogabalin groups for the anxiety subscale and in the 15 mg/day group for the depression subscale.

The LS mean changes from baseline at week 14 for the SF-36 subscales of physical functioning, role-physical, bodily pain, general perception of health, vitality, social functioning, role-emotional, and mental health were greater in all mirogabalin groups vs placebo.

No notable differences were found in the percentage of patients with allodynia and those with hyperalgesia at week 14 between the treatment groups.

3.3. Safety and tolerability

The most common TEAEs (≥5%) are summarized in Table 3. The most common TEAEs were somnolence, dizziness, weight increase, and edema; all occurred more frequently in all mirogabalin groups than in the placebo group. The incidence of somnolence, dizziness, and edema increased as the daily dose of mirogabalin increased. Overall, the majority of the most common TEAEs were mild or moderate, and all resolved without treatment.

Forty-eight patients (6.3%) had ≥1 TEAE leading to treatment discontinuation: 12 (4.0%) in the placebo group, 8 (5.3%) in the 15 mg/day group, 16 (10.5%) in the 20 mg/day group, and 12 (7.7%) in the 30 mg/day group. Fifteen patients, 5 in the 15 mg/day group, 2 in the 20 mg/day group, 3 in the 30 mg/day group, and 5 in the placebo group, had a serious TEAE. No specific serious TEAEs were reported more frequently in any treatment group, and overall, the incidence of serious TEAEs was low. Three
patients, 2 in the mirogabalin 30 mg/day group and 1 in the placebo group, had a severe TEAE of increased blood creatine phosphokinase; all resolved without treatment. Other severe TEAEs included Meniere disease, acute myocardial infarction, and radius fracture in the placebo group; pneumonia, rib fracture, and femur fracture in the 15 mg/day group; erectile dysfunction, fracture, and upper-limb fracture in the 20 mg/day group; and memory impairment, altered state of consciousness, cerumen impaction, and electrocardiogram change in the 30 mg/day group.

No notable changes were observed in electrocardiograms, vital signs, neurological examination, hematology, blood chemistry, or urinalysis. No patients answered “yes” to any question in C-SSRS regarding suicidal behavior and ideation.

4. Discussion

The findings reported here demonstrate that mirogabalin is effective and well tolerated for the management of PHN in Asian patients. In a large UK database of primary care records, approximately 5.8% of patients with herpes zoster developed PHN; of Japanese adults aged 50 years and older with herpes zoster, approximately 20% developed PHN.13,23 There are 2 possible reasons for this difference. The first reason is the difference in the age of study patients. The data from the study in Japan include patients older than 50 years, whereas the data from the UK study include patients younger than 50 years. The other possible reason for the epidemiologic difference is the late implementation of the herpes zoster vaccine in Japan. The

![Graph](image1.png)

**Figure 4.** Responder rates for ≥30% and ≥50% reduction in baseline ADPS. *P = 0.0363; **P = 0.0405; ***P = 0.0035 ADPS, average daily pain score.

![Graph](image2.png)

**Figure 5.** Changes in PGIC at week 14. Significantly more patients treated with mirogabalin 15 mg/day vs placebo reported a PGIC of “much improved or better (score ≥2),” 36.2% vs 26.4%, P = 0.0318. Significantly more patients treated with mirogabalin 20 and 30 mg/day vs placebo reported a PGIC of “minimally improved or better (score ≥3),” 69.3% and 69.0% vs 54.5%, respectively; P = 0.0025 and 0.0028, respectively. *P = 0.0318; **P = 0.0025; ***P = 0.0028. PGIC score ≤2 “much improved or better;” PGIC ≤3 “minimally improved or better.” PGIC, patient global impression of change.
possibly contributed to the lower baseline total ADPS, which in pain score on VAS of SF-MPQ at screening and randomization, or a daily assay sensitivity, particularly, patients with a pain scale. Patients who reported extreme pain as a method to improve the treatment group and small number of differences in discontinued subjects for each applied; we believe that the impact on the results would be limited if a more appropriate approach had been applied; however, if a more appropriate approach had been applied, we believe that the impact on the results would be limited because of the small number of discontinued subjects for each treatment group and small number of differences in discontinued subjects between treatment groups in our study.

The most common AEs were somnolence, dizziness, and weight increase, which were expected based on the mechanism of action of mirogabalin, and a similar result was reported in the phase 2 DPNP study of 5 weeks in the United States. In the phase 2 study by Vinik et al., mirogabalin 30 mg/day had a higher incidence of somnolence (12.3% vs 8.0%) and dizziness (15.8% vs 6.0%) vs pregabalin 300 mg/day. To reduce AEs, this study adopted more gradual titration of mirogabalin compared with the US phase 2 study. When indirectly comparing the current phase 3 TEAEs with the treatment-related AEs reported for pregabalin 300 mg/day in the phase 3 study of Japanese patients with PHN, the incidence of somnolence was similar with mirogabalin 30 mg/day vs pregabalin 300 mg/day (23.9% vs 24.7%), but the incidence of dizziness and weight increase were lower (15.5% vs 30.3%, 5.2% vs 16.9%, respectively). Periocular edema, a common AE in the pivotal studies of pregabalin for DPNP and PHN, also occurred at lower incidence in mirogabalin 30 mg/day group compared with pregabalin 300 mg/day (2.6% vs 12.4%). This result supports the use of mirogabalin as an alternative therapeutic option for PHN.

Mirogabalin can be flexibly selected depending on individual patient response and tolerability in a dose range from 15 to 30 mg/day. In this study, there was a titration period for each mirogabalin group; mirogabalin 5 or 10 mg/day was administered for the first 5 days, then increased in a step-wise manner. The step-wise increase in dosing for α₅β₃ ligands helps increase patient tolerance and decrease AEs; the Japanese Society of Pain Clinicians recommend starting pregabalin at initial doses of 25 mg/day and increasing by 25 to 150 mg/day every 3 to 7 days. For the ideal dosing frequency, because elimination half-life of mirogabalin is estimated to be about 3 hours, plasma concentration of mirogabalin reaches baseline approximately 12 hours after administration. Thus, twice-daily dosing is the reasonable dosing frequency.

In addition, the incidence of somnolence and dizziness (common AEs of gabapentinoids) are correlated with the maximum plasma concentration (Cmax) with internal assessment; this leads us to believe that the incidence of somnolence and dizziness will be lower when administered twice daily vs once daily (data will be published later). Regarding more frequent doses, such as 3 times daily, we did not try this regimen from the viewpoint of drug compliance and patient convenience.

This study has a few limitations. First, only Asian patients were enrolled in the study; studies have shown there may be difference in pain intensity between ethnic groups. However, the phase 2 DPNP study was conducted in the United States, with 72.3% of patients being white and 24.1% of patients being black, and had favorable results for mirogabalin, which suggest mirogabalin might be efficacious in patients of different ethnicities. Second, all patients met the inclusion criteria of creatine clearance of >80 mL/minute as determined by the Cockcroft–Gault equation, so efficacy in patients with PHN and renal impairment cannot be
determined from this analysis. Further studies are needed to determine the appropriate doses for these patients.

An additional limitation of this study is that the patients who received the 15 mg/day dose only received the medication at night. This could lead to decreased AEs during the day, including decreased daytime somnolence. The decrease in daytime AEs for the 15 mg/day group and also for the group that received placebo could result in potential unintended unblinding for the investigators.

The abuse liability of mirogabalin was not evaluated in this study; 2 randomized, double-blind, placebo-controlled studies using either pregabalin or diazepam as positive controls were undertaken; and the results will be reported in a separate publication.

In summary, mirogabalin has demonstrated a well-balanced profile of efficacy and safety and may provide an alternative therapeutic option for the treatment of PHN.

Conflict of interest statement

E. Murayama, M. Sugihara, N. Matsui, S. Ohwada, and Y. Kakehi are employees of Daiichi Sankyo Co., Ltd. J. Kato reports personal fees from Daiichi Sankyo Co., Ltd; during the conduct of the study; and personal fees from Pfizer Japan Inc; Eisai Co, Ltd; and Mochida Pharmaceutical Co, Ltd.

Parts of these study results were presented at the 52nd Annual Meeting of the Japan Society of Pain Clinicians, July 19–21, 2018, Tokyo, Japan.

Acknowledgments

Writing and editorial assistance, under consideration by Daiichi Sankyo authors, was provided by Jennifer Meyering, RN, MS, of AlphaBioCom, LLC, King of Prussia, PA, and supported by Daiichi Sankyo, Co., Ltd., Basking Ridge, NJ. This study was funded by Daiichi Sankyo Co., Ltd. and Daiichi Sankyo, Inc. The authors thank the following investigators for their assistance in the clinical trials: Toshimitsu Kawashima (Abashiri Dermatology Clinic); Mitsuko Mimura (NTT East Sapporo Hospital); Ichiro Tsukinaga (KKR Sapporo Medical Center); Fumio Tanioka (Sapporo Asabu Clinic); Hiroshi Sugawara (Kokubu Dermatology Clinic); Yuko Morita (Maruyama Lila Clinic); Hirofu Fudeta, Hideyuki Toukairin (Sendai City Hospital); Hisashi Date (Sendai Clinic); Yuko Nomura (Nomura Dermatology Clinic); Toshiyo Asai (Asai Dermatology Clinic); Etsuro Hainj (Hajiri Pain Clinic); Yumito Suzuki (Suzuki Pain Clinic); Ken Watanabe (Yokohama City Minato Red Cross Hospital); Shigeuyuki Tai (Tai Clinic); Riika Hayashi (Yokohama Bashamichi Skin & Pain Clinic); Shunichi Nitta (Ishikawa Prefectural Central Hospital); Fumiake Abe (Yamanashi Prefectural Central Hospital); Fuyuko Arakura (National Hospital Organization Matsumoto Medical Center Matsu- moto Hospital); Masao Fukuizawa (Ina Central Hospital); Shoko Urano (JA Shizuoka Koseinen Enshu Hospital); Akihito Mizutani (Mizutani Pain Clinic); Manabu Inuzuka (Chutoen General Medical Center); Hironaka Tsunobuchi (Fujita Health University Banbun-tane Hotokukai Hospital); Masanari Kodera (JCHO Chukyo Hospital); Hideaki Kato (Yachiyo Hospital); Tetsuro Ono (Narita Memorial Hospital); Daisuke Watanabe (Aichi Medical University Hospital); Tomomasu Kimura (Kimura Clinic); Koji Habe (Mie University Hospital); Sei Fukui (Shiga University of Medical Science Hospital); Ken Sasagi (Sasagi Pain Clinic); Atsuko Kato (Osaka Kaisei Hospital); Mari Igashiyama (Nissay Hospital); Yoichi Matsuda (Osaka University Hospital); Ryuta Ikegami (JCHO Osaka Hospital); Taeko Yoshikawa (Hokuketsu General Hospital); Masahiro Morimoto (Kindai University Hospital); Mami Morimoto (Yusaido Morimoto Clinic); Akihiro Kume (Dermatology and Ophthalmology Kume Clinic); Yumiko Takao (Kobe University Hospital); Ichiro Kurokawa (Meiwa Hospital); Lynn Maeda (Nishinomiya Municipal Central Hospital); Harumasa Nakamura (Nakamura Clinic); Kien Park (Paku Pain Clinic); Fujio Yamamoto (Asahi Yamamoto Pain Clinic); Hiroshi Inamari (Japanese Red Cross Wakayama Medical Center); Wook-kang Huh (Dr. Huh’s Dermatology Clinic); Katsuyuki Moriwaki (National Hospital Organization Kure Medical Center and Chugoku Cancer Center); Itsuo Nakagawa (Chugoku Rosai Hospital); Hirofumi Morkawa (Hiroshima General Hospital); Hidenori Harada (Yamaguchi University Hospital); Haruhiko Manabe (Kitakyushu Municipal Medical Center); Bungo Ohyama (Kurume University Hospital); Reiji Kaieda (Fukukawa Tokushukai Medical Center); Shu Iwanaga (Yagi Hospital); Masakazu Nagata (Nagata Dermatology Clinic); Shunichi Ariyoshi (Ariyoshi Clinic); Keiji Okubo (Okubo Skin Care and Clinic); Keizo Matsuo (Matsuo Clinic); Shinichi Koba (Saga-ken Medical Centre Koseikan); Ryo Katsuki (National
Hospital Organization Ureshino Medical Center); Tetsuya Sakai, Itsuko Shibata (Nagasaki University Hospital); Takahiro Tamura (Tamura Dermatology Clinic); Kentaro Okuda (Oita University Hospital); Toru Fujiyuki (Fujiyuki Clinic); Nozomu Toyama (Toyama Dermatology Clinic); Takeshi Uno, Shingo Tateyama (Junwakai Memorial Hospital); Takaki Hashiguchi (Hashiguchi Dermatology); Sang Chul Lee, Jeo Youn Moon (Seoul National University Hospital); Hye Jung Park (The Catholic University of Korea, Seoul St. Mary’s Hospital); Pyung-Bok Lee (Seoul National University Bundang Hospital); Duck Mi Yoon (Severance Hospital, Yonsei University); Jung-Ju Choi (Gachon University Gil Medical Center); Myoung Dong Lee (Chung-Ang University Hospital); Hwa-Yong Shin (Chung-Ang University Hospital); Dae-Hyun Jo (The Catholic University of Korea, Daejeon St. Mary’s Hospital); Woo Seog Sim (Samsung Medical Center); Young-Hoon Jeon (Kyunghoook National University Hospital); Young Deog Cha (Inha University Hospital); Sang Sik Choi (Korea University Guro Hospital); Won Hyung Lee (Chungnam National University Hospital); Jeong Hun Su (Asan Medical Center); Hye-Won Lee, Ji-Yong Park (Korea University Anam Hospital); Haekh Soo Park, Won-joong Kim (Ewha Womans University Mokdong Hospital); SangGon Lee (Daegu Fatima Hospital); Jae Hun Kim (Konkuk University Medical Center); Myoung Jin Ko, Sang Eun Lee (Inje University Haeneundae Paik Hospital); Yeon-Dong Kim (Workum Medical University Hospital); SunOk Song (Yeungnam University Hospital); Kyung-Hoon Yim, Chanjin Park (Chungbuk National University Hospital); Joon Ho Lee (Soon Chun Hyang University Hospital Bucheon); JiHee Hong (Keimyung University College of Medicine); Myung Ha Yoon (Chonnam National University Medical School); Jong Hwan Kim (University Bundang Hospital); Kang Hyoung Lee, Ji Seong Lee (Seoul National University Bundang Hospital); Jihoon Jung, Ji-Young Lee (Kaohsiung Medical University). Supported by the R&D Program of the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Health 21 Project: HI15C1833) and a grant from the Korea Healthcare Technology R&D Project funded by the Ministry of Health & Welfare, Republic of Korea (HI16C0025).}

**Article history:**
Received 8 August 2018
Received in revised form 10 January 2019
Accepted 14 January 2019
Available online 24 January 2019

**References**

[1] Ahn H, Weaver M, Lyon DE, Kim J, Choi E, Staud R, Fillingim RB. Differences in clinical pain and experimental pain sensitivity between Asian Americans and whites with knee osteoarthritis. Clin J Pain 2017;33:174–80.

[2] Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, Kadurin I, Sri Ranjan Y, Fernandez-Alacid L, Millar NS, Dickenson AH, Lujan R, Dolphin AC. The increased trafficking of the calcium channel subunit alpha2delta1 to presynaptic terminals in neuropathic pain is inhibited by the a2δ ligand pregabalin. J Neurosci 2009;29:4076–88.

[3] Berger A, Sadosky A, Dukes E, Edelsberg J, Oster G. Clinical characteristics and patterns of healthcare utilization in patients with peripheral neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurol 2012;12:8.

[4] Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28:586–604.

[5] Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kim K, Kitano Y. Binding characteristics and analogic effects of mirogabalin, a novel ligand for the alpha2delta2 subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 2018;365:573–82.

[6] Drolet M, Brisson M, Schmadter KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010;182:1731–6.

[7] Dworin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274–83.

[8] Dworin RH, Turk DC, Ferrar JT, Haythornthwaite JA, Jensen MP, Katz NP, McKenzie RS, Stucki G, Allen RR, Bellamy N, Carr DB, Chandy K, Cowan P, Dionne R, Guler BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quesney S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Toftet J, Wernicke J, Witter J. IMPACT recommendations. Core outcome measures for chronic pain clinical trials: IMPACT recommendations. PAIN 2005;115:9–19.

[9] Dworin RH, Turk DC, Pierce-Sandher S, Burke LB, Ferrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerra RD, Kerpen R, Kopecky EA, Lissim D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Richards AS, Sampaio C, Slavkasevich V, Sommerville K, Stacey BK, Taylor J, Tesfai H, Treantacostam MA, Wasan AD, Wells G, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMPACT recommendations. PAIN 2012;153:1148–58.

[10] Dworin RH, Turk DC, Wynych KW, Beaton D, Cleenland CS, Ferrar JT, Haythornthwaite JA, Jensen MP, Kerra RD, Aden DR, Brandenburg N, Burke LB, Cella D, Chandy K, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, Quayle HJ, Patel S, Porter L, Quesney S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmadter KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMPACT recommendations. J Pain 2008;9:105–21.

[11] Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T, Bramble S, Corradi L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D. Identification of the a2δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 2006;103:7162–7.

[12] Finnerup NB, Altal N, Haroutunian S, McNeil C, Baron R, Dworin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kameerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73.

[13] Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, Minasian G, Langan SM. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology 2016;87:94–102.

[14] Katz J, Cooper EM, Walther RR, Sweeney EW, Dworin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342–8.

[15] Kernard MG, Molenberghs G, Thijis H. Pattern-mixture models with proper time dependence. Biometrika 2003;90:53–71.

[16] Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson AH, Feng G, Luo ZD. Calcium channel a2δ-1 subunit mediates spinal hyperexcitability in pain modulation. PAIN 2006;125:20–34.

[17] Li CY, Yu YP, Zhou C, Kim DS, Lin B, Sharp K, Steward O, Luo ZD. Calcium channel alpha2delta1 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptic transmission. J Biol Chem 2014;289:7025–37.
[18] Mallinckrodt CH, Lane P, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J 2008;42:303–19.

[19] Merante D, Rosenstock J, Sharma U, Feins K, Hsu C, Vinik A; DS-5565-A-U201 US Phase 2 Study Investigators. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med 2017;18:2198–207.

[20] Ogawa S, Suzuki M, Arakawa A, Araki S, Yoshiyama T. Efficacy and tolerability of pregabalin for postherpetic neuralgia: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Jpn Soc Pain Clinicians 2010;17:141–52.

[21] Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837–42.

[22] Rubin D. Multiple imputation for nonresponse in surveys. New York: John Wiley, 1987.

[23] Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomii Y, Ishikawa T, Okuno Y, Mori Y, Asada H, Yamanishi K, Iso H. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol 2015;25:617–25.

[24] The Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain (Revised) of JPSC. Guidelines for the pharmacologic management of neuropathic pain. 2nd ed, 2016 Japan Society of Pain Clinicians, Toyko, Japan.

[25] Vehof J, Sillevis Smitt-Kamminga N, Nibourg SA, Hammond CJ. Predictors of discordance between symptoms and signs in dry eye disease. Ophthalmology 2017;124:280–6.

[26] Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; Investigators D-AUUPIS. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care 2014;37:3253-61.